AMLX
HealthcareAmylyx Pharmaceuticals, Inc. · Biotechnology · $1B
What is Amylyx Pharmaceuticals, Inc.?
Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
Amylyx is advancing a pipeline centered on AMX0035, a dual-mechanism compound designed to reduce neuronal cell death. The company generates no commercial revenue at this stage, funding operations through capital markets while pursuing regulatory and clinical milestones for its lead asset and potential extensions into other neurodegenerative indications.
Founded in 2013 and headquartered in Cambridge, Massachusetts.
- AMX0035 for ALS treatment
- AMX0035 pipeline extensions for other neurodegenerative diseases
- Dual UPR-Bax apoptosis inhibition platform
Is AMLX a Good Stock to Buy?
UQS Score rates AMLX as Poor overall.
The Risk pillar stands out as the relative bright spot in AMLX's profile, suggesting the company carries a more manageable near-term risk profile compared to some clinical-stage peers.
Quality, Growth, Moat, and Valuation all register weak or elevated readings, reflecting the challenges typical of a pre-revenue clinical-stage company with an uncertain commercial path.
See the exact pillar breakdown and full financial metrics by signing up for a Pro membership at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does AMLX pay dividends?
No — Amylyx Pharmaceuticals, Inc. does not currently pay a dividend.
AMLX does not pay a dividend. As a clinical-stage company, Amylyx directs available capital toward research, clinical trials, and pipeline development rather than shareholder distributions — a common approach for early-stage biopharmaceuticals.
When does AMLX report earnings?
Amylyx Pharmaceuticals reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a clinical-stage company, quarterly results primarily reflect operating expenses and cash runway rather than revenue growth. Pipeline progress and clinical data readouts tend to be more meaningful near-term catalysts than earnings beats.
For the most recent quarter's results, visit Amylyx Pharmaceuticals' investor relations page directly.
AMLX Price History
-24.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Amylyx Pharmaceuticals, Inc.?
Based on Amylyx Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Amylyx Pharmaceuticals do?
Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for ALS and other neurodegenerative diseases. Its lead candidate, AMX0035, is designed to inhibit two pathways involved in neuronal cell death.
Does AMLX pay dividends?
No, AMLX does not pay a dividend. The company is in a clinical stage with no commercial revenue, so capital is reinvested into research and development rather than returned to shareholders.
When does AMLX report earnings?
Amylyx reports on a quarterly basis, as required for US-listed companies. For exact dates and the most recent results, check the investor relations section of the Amylyx Pharmaceuticals website.
Is AMLX a good stock to buy?
UQS Score rates AMLX as Poor overall, with weak readings across most pillars and an elevated Valuation label. The complete pillar breakdown is available to Pro members and can help inform your own research.
Is AMLX overvalued?
The UQS Valuation pillar for AMLX is rated Elevated, suggesting the current market price may not be well-supported by the company's fundamentals at this stage of development.
What is AMLX's market cap bracket?
AMLX is classified as a small-cap stock, which is typical for clinical-stage biopharmaceutical companies that have not yet reached commercial scale.
Is AMLX a long-term quality investment?
From a long-term quality standpoint, AMLX's UQS profile currently rates Poor, with weak Quality, Growth, and Moat scores. Clinical-stage companies carry inherent uncertainty, and long-term outcomes depend heavily on pipeline success.
Who founded Amylyx Pharmaceuticals?
Amylyx Pharmaceuticals was founded in 2013. For detailed founding history and leadership background, the company's official website and public filings are the most reliable sources.
Unlock Full AMLX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar scores for AMLX
- ✓Access detailed financial metrics and trend data
- ✓Compare AMLX against clinical-stage peers side by side
- ✓Get the complete analyst view available only to Pro members
Pro Analysis
AMLX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 8, 2026 | 13.6 | 0.0 | 3.0 | 18.5 | 61.3 | 0.0 | 0.0 |
| Apr 22, 2026 | 13.6 | 0.0 | 3.0 | 18.5 | 60.9 | 0.0 | -0.9 |
| Apr 2, 2026 | 14.5 | 0.0 | 3.0 | 23.1 | 60.9 | 0.0 | — |
AMLX — Pillar Breakdown
Quality
— 0.0/100 (25%)Amylyx Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 18.5/100 (20%)Amylyx Pharmaceuticals, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 61.3/100 (15%)Amylyx Pharmaceuticals, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Amylyx Pharmaceuticals, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 3/100 (25%)Amylyx Pharmaceuticals, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for AMLX.
Score Composition
Financial Data
More Stock Analysis
How is the AMLX UQS Score Calculated?
The UQS (Unified Quality Score) for Amylyx Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Amylyx Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Amylyx Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.